Labcorp (NYSE:LH) Price Target Raised to $365.00

by · The Markets Daily

Labcorp (NYSE:LH – Free Report) had its price objective boosted by Truist Financial from $350.00 to $365.00 in a report published on Monday, MarketBeat.com reports. The brokerage currently has a buy rating on the medical research company’s stock.

LH has been the topic of a number of other reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $306.00 price objective on shares of Labcorp in a research report on Friday, July 31st. JPMorgan Chase & Co. raised their target price on shares of Labcorp from $330.00 to $360.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. Piper Sandler lifted their target price on shares of Labcorp from $300.00 to $309.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Robert W. Baird set a $352.00 price target on shares of Labcorp in a research report on Friday, July 31st. Finally, UBS Group increased their price target on shares of Labcorp from $361.00 to $380.00 and gave the stock a “buy” rating in a research note on Friday, September 11th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $337.73.

View Our Latest Stock Analysis on LH

Labcorp Trading Down 2.4%

NYSE LH opened at $303.93 on Monday. The stock has a market cap of $24.65 billion, a P/E ratio of 25.14, a price-to-earnings-growth ratio of 1.77 and a beta of 0.88. Labcorp has a fifty-two week low of $244.52 and a fifty-two week high of $341.80. The stock has a 50 day simple moving average of $316.74 and a two-hundred day simple moving average of $283.82. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80.

Labcorp (NYSE:LH – Get Free Report) last posted its earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.78 by $0.21. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.The firm had revenue of $3.73 billion for the quarter, compared to analysts’ expectations of $3.71 billion. During the same period in the previous year, the firm earned $4.35 earnings per share. The business’s revenue was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. On average, analysts forecast that Labcorp will post 18.32 earnings per share for the current year.

Labcorp Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 28th were given a dividend of $0.72 per share. The ex-dividend date of this dividend was Friday, August 28th. This represents a $2.88 annualized dividend and a yield of 0.9%. Labcorp’s dividend payout ratio (DPR) is currently 23.82%.

Insider Activity

In other news, EVP Bryan Vaughn sold 234 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total value of $66,968.46. Following the sale, the executive vice president directly owned 6,746 shares of the company’s stock, valued at $1,930,637.74. This represents a 3.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kerrii Anderson sold 3,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $318.02, for a total transaction of $954,060.00. Following the completion of the transaction, the director owned 6,563 shares of the company’s stock, valued at approximately $2,087,165.26. The trade was a 31.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 8,919 shares of company stock worth $2,826,593. 0.84% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Labcorp

Several large investors have recently made changes to their positions in the business. QRG Capital Management Inc. boosted its position in shares of Labcorp by 12.2% in the 2nd quarter. QRG Capital Management Inc. now owns 3,626 shares of the medical research company’s stock worth $1,015,000 after purchasing an additional 393 shares in the last quarter. Sequoia Financial Advisors LLC increased its position in Labcorp by 5.5% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 127,231 shares of the medical research company’s stock valued at $35,625,000 after buying an additional 6,595 shares in the last quarter. Tidal Investments LLC increased its position in Labcorp by 12.4% during the 2nd quarter. Tidal Investments LLC now owns 30,559 shares of the medical research company’s stock valued at $8,557,000 after buying an additional 3,372 shares in the last quarter. Capital Analysts LLC raised its stake in Labcorp by 0.5% during the second quarter. Capital Analysts LLC now owns 15,250 shares of the medical research company’s stock valued at $4,270,000 after buying an additional 79 shares during the last quarter. Finally, NorthRock Partners LLC raised its stake in Labcorp by 6.7% during the second quarter. NorthRock Partners LLC now owns 2,099 shares of the medical research company’s stock valued at $588,000 after buying an additional 132 shares during the last quarter. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Labcorp News Roundup

Here are the key news stories impacting Labcorp this week:

  • Positive Sentiment: At its 2026 Investor Day, Labcorp highlighted potential acquisitions and continued investment in laboratory technology. These initiatives could expand its testing capabilities, improve efficiency and support longer-term revenue growth. Labcorp Holdings Eyes Acquisitions and Lab Tech Investment After 2026 Investor Day
  • Positive Sentiment: Labcorp reaffirmed its long-term earnings outlook, signaling continued confidence in demand for clinical testing and its operating strategy. The company’s previously reported quarterly results also exceeded analyst expectations for earnings and revenue. Labcorp Reaffirms Long-Term Earnings Outlook
  • Positive Sentiment: Baird raised its price target for Labcorp to $361 from $352 and maintained an Outperform rating, indicating that the analyst sees upside despite industry and reimbursement risks. Baird Adjusts Price Target on Labcorp Holdings
  • Positive Sentiment: Seeking Alpha upgraded LH to Buy, citing resilient diagnostic demand, new test launches, a diversified biopharma business and solid operating margins. The analysis also noted that Labcorp had outperformed broad-market and healthcare peers year to date. Labcorp’s Future Driven by Clinical Testing Demand
  • Neutral Sentiment: Recent performance coverage indicates LH has generally lagged some competitors in the latest session, even though longer-term performance comparisons remain favorable. Labcorp Stock Underperforms Competitors
  • Negative Sentiment: Medicare’s signals regarding cuts to payment rates for laboratory services weighed on Labcorp and Quest Diagnostics. Investors are concerned that lower reimbursement could pressure revenue, margins and earnings, creating the most immediate reason for the stock’s weakness. Quest Diagnostics and Labcorp Shares Fall on Medicare Payment Concerns

Labcorp Company Profile

(Get Free Report)

Labcorp (NYSE: LH), formerly Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing and related services to physicians, hospitals, health systems, employers, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including molecular, genetic, oncology, women’s health, infectious disease and pathology services.

Read More